Keros Therapeutics price to sales ratio KROS

Market value divided by revenue over the last twelve months, since 2025.

Today, Oct 23, 2026: 14.9×
Peer median: 1.4×

Keros Therapeutics' price to sales ratio is 14.9× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	14.9×	0.9×	15.8×
2025	2.6×	2.0×	167×

Against its peers

Companies in Drug Manufacturers - General nearest Keros Therapeutics' size, closest first, today.

Company	Price to sales ratio
KROSKeros Therapeutics	14.9×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
LFVNLifevantage	0.4×
COLLCollegium Pharmaceutical	0.9×
SPROSpero Therapeutics	1.4×
ABUSArbutus Biopharma	4.6×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Keros Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.